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It is well documented (1) that parental injection of bacterial endotoxin results in
extensivehemorrhagicnecrosisofmost solidmurine tumors, butincompleteregression
ofonly some. There is evidence (2) that the tumors that undergo complete regres-
sion are those that are ofsufficient immunogenicity, and that regression, as opposed
to hemorrhagic necrosis, is immunologically mediated. In support ofthis interpre-
tation are publishedresults showing(3)that, inthe case ofatleast one immunogenic
murine tumor, endotoxin-induced regressiondependsonthe acquisition bythe host
ofa sufficient number oftumor-sensitized CD4+ T cells at the time that endotoxin
is given. It was suggested (4), on the basis ofthis and other evidence, that the ther-
apeutic action ofendotoxin depends on its ability to induce an intratumor hemor-
rhagic reaction that is destructive enough to reduce the tumor to a size that host
concomitant immunity is capable of rejecting.
Most evidence favors theview that endotoxin-inducedtumorhemorrhagicnecrosis
is mediated by THE It is known, for example, that natural TNF from appropriate
endotoxin-treated donor mice, and rTNF, can substitute for endotoxin in causing
tumor hemorrhagic necrosis (5-8). Again, endotoxin-induced tumor hemorrhagic
necrosis hasbeen shown to be associated with the intratumor synthesis ofTNT (4),
and neutralization ofthis TNF by treating the host with an antiTNF antibody can
partially inhibit tumor hemorrhagic necrosis (4).
Because macrophages are the predominant producers ofTNF, and because these
cells arehighly represented in tumors (9), it islikely thattheyarethe principlesource
ofintratumor TNF (10, 11). However, the ability ofmacrophages to make TNF in
vitro can be blocked by treating them with glucocorticoids (12). It was anticipated,
therefore, that glucocorticoid treatment would also block endotoxin-induced in-
tratumor TNF production in vivo and consequently tumor hemorrhagic necrosis.
Thepurposeofthispaperis to show that this isthe case. Itwill also showthat, whereas
glucocorticoid treatment inhibits the ability of endotoxin to cause tumor hemor-
rhagic necrosis and regression, it has no inhibitory effect on tumor hemorrhagic
necrosis and regression caused by exogenous THE
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Materials and Methods
Mice.
￿
AB6F, (A/J x C57BL/6) female mice were used when they were 10-12 wk old.
They were purchased from The Trudeau Institute Animal Breeding Facility, and were free
of common viral pathogens according to the results of tests routinely performed by Charles
River Professional Services, Wilmington, MA.
Tumor.
￿
The SAl spindle cell sarcoma syngeneic in A/J mice was obtained some years ago
from The Jackson Laboratories, Bar Harbor, ME. It was passaged as an ascites and prepared
for initiating tumors as described previously (13). Tumors were initiated intradermally in
the abdominal region by implanting 106 tumor cells in 0.05 ml of PBS. Tumor growth and
regression was followed by monitoring changes in the mean of two diameters measured at
right angles with dial calipers.
Endotoxin and TNF.
￿
Murine rTNF was a gift from Dr. Jan Tavernier of the University
of Ghent, Belgium. It has a specific activity of 1.37 x 108 U/mg protein, and contained <10
ng endotoxin/mg (13). Endotoxin (Salmonella enteritidis, batch 3105-25) was obtained from Difco
Laboratories, Detroit, MI. Both reagents were dissolved at appropriate concentrations in
PBS. They were injected in a volume of 0.2 ml in a lateral tail vein on day 9 oftumor growth.
The dose of rTNF was 105 U, and the dose of endotoxin 25 /Ag.
Quantifying the Tumor Hemorrhagic Reaction.
￿
The rate and extent ofTNF- or endotoxin-induced
intratumor hemorrhaging were quantified by measuring the accumulation in the tumor of
"Cr-labeled syngeneic RBCs infused 1 h earlier in a lateral tail vein (13). Briefly, AB6F1
mice were bled by cardiac puncture into a syringe containing citric acid/dextrose solution.
The RBCs were pelleted and washed by centrifugation in RPMI 1640 medium. To each 0.5
ml of packed red cells was added 0.5 ml of RPMI 1640 medium containing 100 ACi of
Nat"CrO4 having a specific activity of 250-500 mCi/mg (Amersham Corp., Arlington
Heights, IL). The RBCs were suspended and incubated for 1 h at 37°C, washed three times,
and resuspended in 2 ml ofPBS for intravenous infusion. Each mouse was given an infusion
of 0.2 ml of the "Cr-labeled RBC suspension in a lateral tail vein 1 h before treatment with
endotoxin or rTNE To measure intratumor hemorrhaging five mice were killed at 1, 2, 4,
and 6 h after injection of endotoxin or rTNF, their tumors were excised, placed in glass vials,
and the "Cr content per tumor determined with a Rack Gamma II Counter (LKB Instru-
ments, Inc., Gaithersburg, MD) . The results are presented as means of the total counts per
minute per tumor.
Assayfor TNF.
￿
An assay based on the procedure of Wang et al. (14) was used. Briefly,
1.5 x 104 murine L929B cells in 100 p,l of Eagle's MEM (Microbiological Associates,
Walkersville, MD) containing 5 % FCS and antibiotics were placed in wells of 96-well micro-
titer plates and incubated overnight at 37°C in a 5% C02 humidified incubator. Sequential
twofold dilutions ofthe TNFcontaining extracts were made in the same medium containing
2 lcg ofactinomycin D (Calbiochem-Behring Corp., LaJolla, CA), and 100 pl of each dilution
added to replicate wells containing the L929B target cells. After 24 h of incubation cytotox-
icity was scored microscopically. The cytotoxicity titer (U/ml) is defined as the highest dilu-
tion of the test material capable of causing 50% or more destruction of the monolayer of
L929B cells. The assay was used to determine cytotoxic titers ofextracts of tumors from con-
trol and endotoxin-treated mice. Extracts were made by homogenizing whole tumors (10%
wt/vol) in PBS (pH 7.4) containing 10% FCS. Homogenization was done on ice with a motor-
ized blender. The homogenates were centrifuged to pellet tissue debris, and the clarified su-
pernatants assayed as above. Previous studies have shown (4) that TNF is stable during the
extraction procedure, and that all endotoxin-induced cytotoxic activity in tumor extracts is
neutralizable with an anti-rTNF antibody.
Glucocorticoids.
￿
Cortisone acetate suspended in saline (Merck, Sharp and Dohme, West
Point, PA) and dexamethasone 21-acetate (Sigma Chemical Co., St. Louis, MO) dissolved
in ethanol and then in PBS were injected in a volume of 0.2 ml subcutaneously in the nape
of the neck in a dose of 2 or 1 mg, respectively.
Results
Glucocorticoid Treatment Inhibits Endotoxin-induced Hemorrhagic Necrosis and Regres-
sion.
￿
The first experiments were designed to investigate whether intradermal in-jection of 2 mg of cortisone acetate would prevent a 25-jug dose of endotoxin given
intravenously 12 h later from causing hemorrhagic necrosis and regression of a 9-d
SA1 sarcoma. As can be seen in Fig. 1, whereas endotoxin treatment caused an ex-
tensivehemorrhagic reaction in andsubsequent regression ofthe SAl sarcomagrowing
in control mice, it caused neither hemorrhagic necrosis nor complete regression of
the same sized tumor in glucocorticoid-treated mice. There was a small degree of
endotoxin-induced regression of the tumor in cortisone-treated mice, but progres-
sive tumor growth soon resumed.
Fig. 2 shows the results of an experiment designed to determine whether dexa-
methasone was also capable of inhibiting endotoxin-induced hemorrhagic necrosis.
It can be seen that this glucocorticoid given 12 h before endotoxin was as effective
as cortisone acetate in inhibiting hemorrhagic necrosis. Dexamethasone was also
as capable of inhibiting tumor regression (results not shown).
Glucocorticoid TreatmentInhibitsIntratumor TNFProduction.
￿
TableI shows theresults
of an experiment that measured the ability of cortisone acetate or dexamethasone
to inhibit endotoxin-induced synthesis of TNF in a 9-d SA1 sarcoma and in the
host at large. This experiment involved measuring the capacity of serial dilutions
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FIGURE 1. The ability of a
25-,ug i.v. dose of endotoxin
(ENDO) given on day 9 of tu-
morgrowth (arrow)to causein-
tratumor hemorrhaging (right
panel) andtumorregression (left
paneowasseverely inhibited by
an intradermal injectionofcor-
tisone acetate 12 hbefore endo-
toxin(CORT + ENDO). Cor-
tisone acetate alone had little
effect on tumorgrowth. Means
of five mice per group.
FIGURE 2. Dexamethasone (ENDO + DEXAM)
wasas effective as cortisoneacetate(ENDO + CORT)
at inhibitingintratumor hemorrhaging causedby en-
dotoxin (ENDO) given on day 9 of tumor growth.
The tumor hemorrhagic reaction wasmeasured at
its peak 6 h after giving endotoxin. Means of five
tumors per group.706
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TABLE I
Effect of Glucocorticoids on Endotoxin-induced TNF Production
TNF activity (U/organ)
Group
￿
Tumor Spleen Serum
Control
￿
BDL* BDL <16
Endotoxin
￿
4,642 853 512
Cortisone acetate & endotoxin
￿
299
￿
128
￿
<16
Dexamethasone & endotoxin
￿
299
￿
64
￿
<16
On day 9 of SA1 sarcoma growth mice received 2.5 mg of cortisone acetate
or 1 mg of dexamethasone sc 12 h before giving 24 ug i.v. of endotoxin .
Homogenates (10% wt/vol) of five pooled tumors or spleens were prepared .
Homogenate supernatants and pooled sera were assayed for TNF. TNF/organ
= (homogenate vol x TNF U/ml)/5. Total serum TNF assumes 1 ml serum/
mouse.
* TNF activity below detectable levels (BDL) at a 1/16 dilution of supernatant
from a 10°fo wt/vol homogenate.
of extracts of tumors and organs from glucocorticoid-treated and control mice to
lyse L929B target cells in vitro. A previous study showed (4) that all of the cytotox-
icity extractable from the tumors and organs of endotoxin-treated mice is due to
the presence of TNF, and that peak quantities of TNF are synthesized 2 h after en-
dotoxin is given.
It can be seen that 2 h after endotoxin treatment appreciable quantities of TNF
were present in the tumors, spleens, and blood of endotoxin-treated control mice,
and that by far the largest quantity of TNF was present in the tumors. In contrast,
greatlyreducedquantities (10% or less of controls) of TNFwere present in the tumors,
spleen, and blood of endotoxin-treated mice pretreated with glucocorticoids.
Glucocorticoid Treatment Has No Effect on theAbility of Exogenous TNF to Cause Tumor
HemorrhagicNecrosis andRegression. It is well documented that intravenously injected
natural or rTNF results in extensive hemorrhagic necrosis of the centers of murine
tumors, and that in the case of the SA1 sarcoma, hemorrhagic necrosis is followed
by complete tumor regression (4). Given the published evidence that TNF is the
mediator of endotoxin-induced regression (4), and the evidence abovethat glucocor-
ticoids inhibit endotoxin-induced hemorrhagic necrosis by inhibiting endogenous
TNF synthesis, it was anticipated that glucocorticoid treatment wouldhave no effect
on the ability of exogenous TNF to cause hemorrhagic necrosis of the SA1 sarcoma.
It can be seen in Fig. 3 that 2 mg of cortisone acetate given intradermally to mice
bearing a day 9 SAl sarcoma had no effect on the ability of 105 U of rTNF given
intravenously 12 hlaterto causehemorrhagic necrosis and subsequent complete tumor
regression.
Glucocorticoid Treatment Given after the Hemorrhagic Reaction Does NotPrevent Endotoxin
from Causing TumorRegression. It was shown above that the ability of rTNF to cause
hemorrhagic necrosis andsubsequent regression of theSAl sarcomawas not affected
by pretreatingthe host with glucocorticoids. However, it is known (4, 13) that com-
plete regression of this tumor requires that the host possesses an adequate level of
concomitant antitumor immunity. This means that glucocorticoid treatment does
not inhibit host antitumor immunity. It was anticipated, therefore, that glucocorti-E
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FIGURE 3.
￿
Evidence that the
ability of 105 UofrTNF (TNF)
given intravenouslyon day9of
tumor growth to cause in-
tratumor hemorrhaging (right
panel) andtumorregression (left
paneo was notinhibitedby cor-
tisone acetate (CORT + TNF)
given 12 hearlier. Meansoffive
mice per group.
FIGURE 4. Cortisone acetate given intrader-
mallybefore (ENDO + CORT, -12 h), butnot
after (CORT + ENDO, + 5 h) endotoxinon day9
of tumor growth, inhibited endotoxin-induced
tumorregression (ENDO). Meansof five mice per
group.
coid treatment would notpreventendotoxin-induced tumorregression if given after
endotoxin has already caused a hemorrhagic reaction in the tumor.
It was found (Fig. 4) that, whereas cortisone acetate given 12 h before endotoxin
inhibited tumor regression, cortisone acetate given 5 h after endotoxin, when the
tumorhemorrhagic reaction wasalmost complete, waswithout effect. It is apparent,
therefore, that cortisone acetate inhibits endotoxin-induced regression solely by in-
hibiting hemorrhagic necrosis.
Discussion
This study shows that the ability ofendotoxin to cause hemorrhagic necrosis and
subsequent regression of an established subcutaneous SA1 sarcoma is inhibited by
treating thetumor-bearing mice with glucocorticoids 12 h before giving them endo-
toxin. Inhibition of endotoxin-induced hemorrhagic necrosis was shown to be asso-
ciated with inhibition of endotoxin-induced TNF production in the tumor and in
the host at large. On the other hand, glucocorticoid treatment had no effect on the
ability of exogenous TNF to cause hemorrhagic necrosis and regression of the SAl
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sarcoma. Given the published evidence showing that TNF is the primary mediator
of endotoxin-induced tumor hemorrhagic necrosis (4), the results presented here
strongly suggest that glucocorticoids inhibit the antitumor action of endotoxin by
inhibiting its ability to induce the production of TNF
This is notto saythat TNF alone is responsible forendotoxin-induced tumorhemor-
rhagic necrosis. It may also require the participation of already formed host mole-
cules, such as complement component C5 (15), or of induced molecules, such as
IL-1 and other cytokines. However, if other induced molecules are involved, their
induction would need to be resistant to the doses of glucocorticoids used here. It
is known, in this connection, that glucocorticoids can inhibit the synthesis of IL-1
(16-18), as well as TNF(12), by host cellsin vitro, both at the level of gene transcrip-
tion and translation. It seems likely, therefore, that IL-1 is not needed for TNF
mediated tumor hemorrhagic necrosis. Even so, a role for IL-1 and other induced
cytokines cannot be excluded until it is formally demonstrated that they are not in-
volved.
As forTNF itself, it is likely that intratumor macrophages are mainly responsible
for its production in the tumor. It is known that macrophages are major producers
of TNF (8), that these cells can be well represented in tumors (9), and that TNF
appears to be responsible, at least in part, for the ability of macrophages to kill cer-
tain tumor cells in vitro (10, 11). It seems almost certain, however, that TNF does
not cause tumor hemorrhagic necrosis by directly destroying tumor cells in vivo.
On the contrary, it was elegantly demonstrated many years ago (18) that endotoxin-
induced tumor hemorrhagic necrosis is caused by a breakdown in the tumor's vas-
culature and consequently in ischemic death ofmost ofthe central part of thetumor.
This couldresult from adirect cytotoxicaction ofTNFon vascular endothelial cells,
as has shown to be the case in other models of TNFinduced hemorrhagic necrosis
(19). In the study presented here intratumor hemorrhaging was measured in terms
of the intratumor extravasation of S1Cr-labeled syngeneic red blood cells infused in-
travenously shortly before endotoxin or TNF was given.
It needs to be pointed out that the endotoxin-induced vascular breakdown and
ischemic death of the center of the tumor is not sufficient to cause complete tumor
regression. In order for the rim of living tumor tissue that survives hemorrhagic
necrosis to undergo complete regression, it is necessary forthehost to be in the pro-
cess of generating an adequate level of concomitant antitumor immunity (4). The
finding that glucocorticoids failed to inhibit the ability of exogenous TNF to cause
hemorrhagic necrosis, or subsequent tumorregression, means that thesecompounds
did not significantly depress antitumorimmunity. Therefore, theirabilityto inhibit
the antitumor action of endotoxin must have been based solely on their ability to
inhibit hemorrhagic necrosis. It is apparent, therefore, that hemorrhagic necrosis
serves to reduce the tumor burden to a size that can be completely rejected by an
otherwise subtherapeutic level of concomitant immunity.
Because the tumor hemorrhagic reaction can be viewed as a tissue destructive
inflammatory reaction caused by the local synthesis of TNF, its inhibition by glucocor-
ticoids indicates that it might serve as a useful model to study in more detail the
antiinflammatory action of glucocorticoidsand antiinflammatory agents in general.Intravenous injection of 25 ug of bacterial endotoxin on day 9 of growth of the
SAl sarcoma results in extensive necrosis of the core of thistumorand in its subse-
quent complete regression . Tumor hemorrhagic necrosis and regression failed to
'
￿
given a subcutaneous injection ofcortisone acetate or dexa-
methasone 12 h before being giving endotoxin. Inhibition of tumor hemorrhagic
necrosis and regressionby glucocorticoids was associated with inhibition ofendotoxin
induced intratumor TNF production that normally takes place severalh after endo-
toxin is given . In contrast, glucocorticoids had no effect on the ability of intrave-
nously injectedrTNF to causetumor hemorrhagic necrosis and regression. The results
lend further support to the beliefthatTNF is the predominant mediator of endotoxin-
inducedhemorrhagic necrosis ofestablished murine tumors, and that hemorrhagic
necrosis is a prerequisite for the immunologically mediated regression that follows .
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